Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google
ENTITY
China Traditional Chinese Medicine (570 HK)
Watchlist
291
Analysis
Health Care
•
Hong Kong
China Traditional Chinese Medicine Co. Limited, through its subsidiaries, manufactures and sells medicine and pharmaceutical products in China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
China Traditional Chinese Medicine
•
21 Jan 2025 00:55
China TCM (570.HK) - About the Profit Warning and the Valuation Outlook
China TCM's performance decline in 2024 aligns with expectations, but there is hope for future profit growth based on new management. Focus on...
Xinyao (Criss) Wang
Follow
678 Views
Share
bearish
•
China Traditional Chinese Medicine
•
08 Dec 2024 01:43
China Healthcare Weekly (Dec.8) - TCM VBP Update, GLP-1's Good Story Broke, China TCM's Sudden Rally
Hubei's TCM patent medicine VBP will impact Shineway's performance. Caution needed on GLP-1 market outlook. There's no evidence to support CNPGC’s...
Xinyao (Criss) Wang
Follow
448 Views
Share
bearish
•
China Traditional Chinese Medicine
•
21 Oct 2024 06:22
TCM (570 HK): Likely Rush for The Exits As Deal Busts
How does a ~34% decline (in the morning session) stack up with past deal breaks in Hong Kong? It's not a clean comparative analysis, as past...
David Blennerhassett
Follow
1.2k Views
Share
bearish
•
China Traditional Chinese Medicine
•
18 Oct 2024 15:12
China Traditional Chinese Medicine (570 HK): Disaster as Offer Lapses, Potential Deal Break Price
This deal break caught many, including me, off guard. There are lessons to be learnt and questions to be asked. Shareholders will have a bruising...
Arun George
Follow
1.2k Views
Share
bearish
•
China Traditional Chinese Medicine
•
05 Nov 2024 00:55
China TCM (570.HK) Update - The Real Reason For the Deal Break and the Valuation Outlook
China TCM's decision to abandon privatization may be due to national security concerns. We lowered 2024 forecast. Valuation rebound rely on...
Xinyao (Criss) Wang
Follow
704 Views
Share
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.45.1
x